Scancell (LSE:SCLP) While vaccine developers Moderna, Astrazeneca and Pfizer have seen significant share price growth since announcing their Covid-19 drug trials, the real opportunity for retail...
Covid-19
Open Orphan leads weighty Wellcome Trust bid to define human challenge drug standards
Open Orphan (LSE:ORPH) Open Orphan subsidiary hVIVO has been selected to lead a highly-respected group to create international standards for drugs used in human challenge trials. The...
The second-gen Covid-19 stocks offering explosive opportunities: 4D Pharma
4D Pharma (LSE:DDDD) 4D Pharma (LSE:DDDD) shares have surged from an all-time low of 23.5p in March to hit as high as 122p in recent days. That’s a share price not seen since May 2019. So, could the...
Has the demise of COVID–19 been greatly exaggerated?
On Monday, we witnessed one of the craziest days on the market in recent history. What was going up suddenly went down, and what had looked down and out jumped up and came back alive. The trigger...
The second-gen Covid-19 stocks offering explosive opportunities
Open Orphan (LSE:ORPH) The Covid-19 pandemic will not end with a silver-bullet vaccine. We already know this, so wise traders are instead looking to the companies that do have a shot at helping the...
Round-up: Busy week for Open Orphan as it pushes forward Covid and oncology arms (ORPH)
Open Orphan (LSE:ORPH) has confirmed that it is in advanced negotiations with the UK government for a coronavirus challenge study. In a Thursday update in response to a spike in its share price, the...
Open Orphan announces major contract for Covid-19 vaccine trial (ORPH)
Open Orphan (LSE:ORPH) was looking strong at 13.3p a share on Tuesday following a major breakthrough in its coronavirus operations. The business has signed a deal with biology company Codagenix to...
Key human challenge expert Adrian Wildfire rejoins hVIVO for Open Orphan boost (ORPH)
Anglo-Irish contract research pharma group Open Orphan (LSE:ORPH) has received another boost as key human challenge study expert Adrian Wildfire rejoins the team. Mr Wildfire left Open Orphan...
Open Orphan’s hVIVO expands lab growth revenue with three new contract wins (ORPH)
Open Orphan (LSE:ORPH) has signed new laboratory contracts for its London virology clinic, extending up a new area of business for the pharma services firm. A Tuesday morning RNS detailed how...